Skip to content
10-K

Annual Report

Allogene Therapeutics, Inc. ALLO

0001628280-26-017242

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 10, 2026 243.78M sh
Shares Diluted FY 2025 · Dec 31, 2025 220.62M sh
Shares Diluted FY 2025 · Dec 31, 2024 194.81M sh
Capex FY 2025 · Dec 31, 2025 $386K
Capex FY 2025 · Dec 31, 2024 $694K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$149.25M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$200.3M
Cash And Equivalents FY 2025 · Dec 31, 2025 $51.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $75.22M
Stockholders Equity FY 2025 · Dec 31, 2025 $292.54M
Stockholders Equity FY 2025 · Dec 31, 2024 $422.18M
Stockholders Equity FY 2025 · Dec 31, 2023 $512.23M
Current Liabilities FY 2025 · Dec 31, 2025 $32.51M
Current Liabilities FY 2025 · Dec 31, 2024 $35.52M
Total Liabilities FY 2025 · Dec 31, 2025 $123.36M
Total Liabilities FY 2025 · Dec 31, 2024 $126.53M
Current Assets FY 2025 · Dec 31, 2025 $257.75M
Current Assets FY 2025 · Dec 31, 2024 $303.39M
Total Assets FY 2025 · Dec 31, 2025 $415.91M
Total Assets FY 2025 · Dec 31, 2024 $548.71M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.87
Eps Diluted FY 2025 · Dec 31, 2024 −$1.32
Eps Basic FY 2025 · Dec 31, 2025 −$0.87
Eps Basic FY 2025 · Dec 31, 2024 −$1.32
Sga Expense FY 2025 · Dec 31, 2025 $56.78M
Sga Expense FY 2025 · Dec 31, 2024 $65.21M
Rd Expense FY 2025 · Dec 31, 2025 $150.15M
Rd Expense FY 2025 · Dec 31, 2024 $192.3M
Net Income FY 2025 · Dec 31, 2025 −$190.89M
Net Income FY 2025 · Dec 31, 2024 −$257.59M
Operating Income FY 2025 · Dec 31, 2025 −$209.32M
Operating Income FY 2025 · Dec 31, 2024 −$273.2M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $22K